Skip to main content
. 2017 Nov 1;21(3):242–254. doi: 10.1093/ijnp/pyx096

Figure 3.

Figure 3.

NYX-2925 facilitates NMDA current and NMDA receptor-dependent LTP, while decreasing LTD. (A) NYX-2925 (0.1–0.5 µM) enhanced the pharmacologically-isolated NMDAR current in Schaffer collateral-evoked EPSCs in hippocampal CA1 pyramidal neurons. NYX-2925 (B) enhanced the magnitude of LTP at 0.5 µM and (C) decreased the magnitude of LTD at 5 µM of synaptic transmission at Schaffer collateral-CA1 synapses as compared to untreated control (aCSF) slices. (D) NYX-2925 (0.1 and 0.5 µM) enhanced the magnitude of LTP in layer II/III-evoked normalized field EPSP slopes in rat slices recorded in MPFC layer IV. NYX-2925 was bath applied for 40–50 min starting 20 min before high-frequency theta trains to induce LTP (solid bar) or low-frequency stimulation to elicit LTD (solid bar). LTP/LTD was measured 40 min after high- or low-frequency stimulation. Data are shown as mean ± SEM. N=7 cells per group (A) or 5–10 slices per group (B-D). * P<.05, (A) within-subjects t test vs baseline (B-D) Fishers PLSD post hoc test vs vehicle.